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produce adequate engraftment even when the CD34/kg content
is below what is considered a minimum target for PBSC alone.
Registry data may already exist to address this issue.
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EVIDENCE OF SUCCESSFUL ALLOGENEIC TRANSPLANTAITON USING
CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FROM HEALTHY
DONORS
Kim, D.H.12, Jamal, N.1, Saragosa, R.1, Lipton, J.H.1, Gupta, V.1,
Kuruvilla, J.1, Messner, H.A.1 1Princess Margaret Hospital, Toronto,
ON, Canada; 2Samsung Medical Center, Seoul, Republic of Korea.
Between Sep 2003 and Dec 2005, the BMT program at Princess
Margaret Hospiral (Toronto, ON, Canada) performed 105 trans-
plants using cryopreserved PBSCs from allogeneic related donors.
The current study was aimed to evaluate the safety of cryopreser-
vation of PBSCs, to compare the clinical outcomes of cryopre-
served PBSCT with fresh PBSCT, and to evaluate the inﬂuence of
cryopreservation on colony forming unit (CFU) assay data of
PBSCs incluidng CFU-GM, BFU-E, CFU-MEG and CFU-
GEMM. As a control group, 106 patients receiving fresh PBSCTs
between Jun 2001 and Aug 2003 was compared.
All patients tolerated well to infusion without signiﬁcant toxicity.
The mean viability of thawed products was 71.21.0%. The me-
dian transplant dose of TNC and CD34 cells was 8.9108/Kg
and 5.0106/Kg, while that of CFU-GM, BFU-E, CFU-MEG
and CFU-GEMM was 118, 134, 19, 8.4104/Kg, respectively. No
differences in clinical outcomes were noted between cryo- vs.
fresh-PBSCT group: engraftment of neutrophil (p0.178) or
platelet (p0.785), acute GVHD (p0.113), chronic GVHD
(p0.673), recurrence (p0.295), non-relapse mortality
(p0.340), and overall survival (p0.668). The colony forming
activity was reduced by 24.62.5% for CFU-GM, 30.52.5% for
BFU-E, 61.43.1% for CFU-MEG, and 21.32.1% for CFU-
GEMM after cryopreservation. The transplant CD34 cell dose
correlates well with transplant dose of CFU-GM (p0.001),
BFU-E (p0.001), CFU-MEG (p0.001) and CFU-GEMM
(p0.049), but not with TNC dose. The group receiving higher
transplant CD34 cell dose showed signiﬁcantly faster engraft-
ment of neutrophil (0.5109/L, p0.012) and platelet
(20109/L, p0.013 and 100109/L, p0.009). Moreover,
transplant CFU-MEG dose showed good correlation with engraft-
ment of platelet above 20109/L (p0.029), 50109/L (p0.003),
and 100109/L (p0.001). In multivariate analysis, higher CFU-
MEG dose was strongly correlated with faster engraftment above
100109/L when taking into account as a continuous (p0.001) or
categorical variables (p0.040).
Conclusion
1) Cryopreserved PBSCT is safe in terms of infusion-related
toxocitiy, and showed equivalent transplant outcomes to fresh
PBSCT.
2) CFU-MEG decreases by 60% after cryopreservation, but
other CFUs showed similar decrease as viability.
3) Transplant CD34 cell dose correlated well with engraftment
of neutrophil and platelet. However, in terms of stable platelet
engraftment (100109/L), CFU-MEG dose seemed to be more
important factor than CD34 cell dose.
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DEVELOPMENT OF A MINIMALLY INVASIVE DEVICE AND METHOD FOR
RAPID, OUTPATIENT HARVEST OF BONE MARROW
Kraft, D.1, Milroy, C.1, MacKenzie, A.2, Ghazarossian, V.2 1Stanford
University School of Medicine, Stanford, CA; 2StemCor Systems Inc,
Menlo Park, CA.
Bone marrow is a rich source of adult stem cells. Traditional
methods for harvesting marrow derived stem cells are crude, te-
dious and expensive. We have developed a device and method for
the minimally invasive harvest of bone marrow which may enable
the rapid, convenient outpatient harvest of large quantities of
marrow derived cells under local anesthesia.
Marrow contains a rich supply of hematopoetic, mesenchymal
and other adult stem cell populations. Both marrow and mobilized
peripheral blood stem cells are currently utilized in BMT. For
allogeneic transplants, recent data suggests operatively harvested
marrow (as well as GCSF-primed marrow) may lead to less chronic
GVHD and better overall outcomes than mobilized PBSC grafts.
In addition to BMT, marrow derived cells may soon be utilized in
a variety of stem cell mediated regenerative therapies, resulting in
an increasing need for a simpliﬁed means for easy, rapid and
economical acquisition of bone marrow.
Current operative marrow harvests generally require 200 tro-
car insertions into the donor’s ileac crest, with each puncture/
aspirate enabling withdrawal of a only a small volume of marrow.
O.R. based harvests require general anesthesia, multiple staff, sup-
portive RBC transfusions, and often an overnight hospital stay.
Peripheral blood stem cell harvests, while less invasive, often re-
quire several rounds of expensive GCSF administration and multi-
hours apheresis sessions. Each of these harvest methods incur
average costs over $15,000 per collection.
We have developed a novel harvest device, the “MarrowMiner”
for the rapid, minimally invasive extraction of bone marrow. This
method utilizes a single marrow entry site into the ileac bone,
through which a ﬂexible, powered, guidable catheter is able to
access the majority of the accessible marrow space. The Marrow-
Miner device will enable a single operator to rapidly harvest mar-
row in the outpatient setting, signiﬁcantly facilitating convenient,
on-demand stem cell collection, and should signiﬁcantly reduce
harvest costs and morbidity. Collected marrow could be utilized
immediately, or undergo manipulation for a variety of current and
potential future therapeutic indications.
The MarrowMiner device has been under preclinical develop-
ment in benchtop models, miniature swine and proof of concept
work in human cadavers. Data from device development will be
presented as a clinical grade version is being readied for human use.
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A PILOT TRIAL OF UNRELATED DONOR UMBILICAL CORD BLOOD
TRANSPLANATION (UCBT) AUGMENTED WITH CYTOKINE-PRIMED AL-
DEHYDE DEHYDROGENASE-BRIGHT (ALDHBR) CELLS
Kurtzberg, J.1, Balber, A.2, Mendizabal, A.3, Reese, M.1, Kaestner, A.1,
Gentry, T.2, Hickerson, D.2, Allen, C.3, Sledge, L.S.1, Deibert, E.2,
Allison, J.1, Baker, J.1, Haley, N.R.2 1Duke University Medical Center,
Durham, NC; 2Aldagen Incorporated, Durham, NC; 3The EMMES
Corporation, Rockville, MD.
The major obstacles to UCBT are delayed engraftment and
immune reconstitution due to the lower cell dose. Ex vivo expan-
sion of a portion of the CB graft to increase the number of cells
available for transplantation has been attempted with little to no
affect. We hypothesized that the expanded cells terminally differ-
entiated in culture exhauting their ability to further expand in vivo.
ALDHbr cells in cord blood are enriched for stem and progenitor
cells. These cells were cultured cells ex vivo with expansion of
mature and immature progenitors. We hypothesized that cells
would undergo further expansion if they were primed ex vivo for a
few days and then infused in vivo. We conducted a trial to test the
safety and feasibility of selecting, priming and infusing ALDHbr
cells isolated by high speed ﬂow cytometry from the 20% fraction
of banked CB stored in a dual compartment bags. ALDHbr cells
were isolated 6 days prior to transplant and primed in culture with
cytokines for 5 days. Release criteria included cell count, viability
and negative gram stain. Primed cells were infused 4 hours after
the conventional graft (80% fraction) on day 0. After written
informed consent, patients received sorted but unexpanded cells
(n4) or sorted and primed cells (n10). Safety was the primary
endpoint. Secondary endpoints included engraftment, immune re-
constitution and overall survival. Thus far 14 patients, (55% male,
82% Caucasian, median age 1.16 years) with pediatric malignant
(n6) or non-malignant (n8) diagnoses have been treated. CB
precryopreservation cell dose was 13.8910e7/kg with infused
dose 9.5310e7/kg. Four patients received51037cells/kg from
the 80% fraction. The yield of ALDHbr cells post sort was 50-
110K and remained stable during priming. No patient experienced
infusional toxicity. One patient died of persistant pulmonary hy-
pertension shortly after transplant. The other patients all survive
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